MedTrace Logo

Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)

NCT00560612 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-06-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is: 1) To document the effectiveness and tolerability of paroxetine for the treatment of subthreshold posttraumatic stress disorder (PTSD) in veterans in the early post-deployment period; and 2) To determine the potential efficacy of paroxetine in preventing the progression of anxiety symptoms to PTSD and other anxiety disorders, and improving overall veteran function.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Paroxetine

Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.

DRUG

Placebo

Placebo: same as paroxetine (active comparator)

Sponsors & Collaborators

  • Durham VA Medical Center

    lead FED

Principal Investigators

  • Christine E Marx, MD, MA · Durham VAMC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560612 on ClinicalTrials.gov